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Abstract
This article presents an overview of immunological factors and their role in the development of
endometriosis, with emphasis on inflammatory cytokines, growth and adhesion factors. Although
retrograde menstruation is a common phenomenon among women of reproductive age, not all
women who have retrograde menstruation develop endometriosis. The development of
endometriosis is hypothesised to be a complex process, which may be facilitated by several factors,
including the quantity and quality of endometrial cells in peritoneal fluid (PF), increased
inflammatory activity in PF, increased endometrial-peritoneal adhesion and angiogenesis, reduced
immune surveillance and clearance of endometrial cells, and increased production of
autoantibodies against endometrial cells. Potential biomarkers like cytokines and autoantibodies
upregulated during development of endometriosis may be useful in the development of a non-
surgical diagnostic tool. Although endometriosis can be treated using hormonal suppression, there
is need for non-hormonal drugs, which can inhibit the development of endometriosis and alleviate
pain or infertility without inhibition of ovulation. New molecules that modulate immune function
in endometriosis should be the targets for future research.
Introduction
Endometriosis is a gynaecological disorder characterised
by the presence and growth of endometrial tissues in the
ectopic site. The endometrial deposits are mostly found in
the pelvis (ovaries, peritoneum, uterosacral ligaments,
pouch of Douglas and rectovaginal septum). The preva-
lence of endometriosis among asymptomatic women
ranges from 2–22%, while in women with dysmenor-
rhoea, the incidence of endometriosis is 40% to 60% [1].
It is the most common cause of pelvic pain and occurs in
13%-33% of women with infertility [2]. Although
endometriosis stands as one of the most investigated dis-
orders of gynaecology [3], our current understanding of
aetiology and pathophysiology of the disease remains elu-
sive. Retrograde menstruation is a widely accepted and
proposed mechanism that may explain mostly the pres-
ence of endometrial cells in ectopic sites [4]. However, it
does not account for the fact that these misplaced cells
survive in women with endometriosis and not in healthy
women. An immunological/inflammatory aetiology has
been conjectured, as demonstrated by increased concen-
trations of activated macrophages, cytokines, T cells and B
cells [2]. The endometrial fragments desquamated during
menstruation and deposited into peritoneal cavity,
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lesions. The development of endometriosis may be influ-
enced by quantity and quality of endometrial cells in the
PF, and by immune factors, including increased inflam-
matory activity in PF, impaired immune recognition and
clearance of ectopic endometrial cells, and formation of
autoantibodies. These factors will be discussed in this
review.
Retrograde Menstruation
Several theories exist that attempt to explain the mecha-
nisms involved in development of endometriosis, but
Sampson's theory [4] of retrograde menstruation has
gained most supportive evidence. Retrograde menstrua-
tion is the reflux of menses through fallopian tube to
ectopic site especially the peritoneal cavity. Viable
endometrial cells have been found in the peritoneal cavity
during nonmenstrual phases of the cycle [5] and during
menses (reviewed by D'Hooghe et al. [2]). Although retro-
grade menstruation occurs in 70–90% of women [6] and
83% in baboons [7], endometriosis is diagnosed in at
least 10% of the former and 25% of the latter. If only a
small percentage of all women who have reverse menstru-
ation actually develop the disease, the puzzling enigma is
why the pelvic environment becomes receptive to allow
implantation and proliferation of endometrial cells and
development of endometriosis? Other factors must be
involved allowing retrogradely displaced endometrial tis-
sue to implant and develop into endometriotic lesions. It
has been hypothesized that the quantity of endometrial
cells deposited into the peritoneal cavity during menstru-
ation could be higher among women who develop
endometriosis, as suggested by a positive correlation
between the number of menstrual cycles and the preva-
lence, cumulative incidence and progression of spontane-
ous endometriosis in baboons (reviewed by D'Hooghe
and Debrock [8]). Similarly, it is well known that women
with short cycles and long duration of menstrual flow are
more likely to develop endometriosis [9]. Furthermore,
outflow obstruction of menstrual effluent, resulting in
excessive retrograde menstruation has been associated
with endometriosis both in humans [9,10] and in
baboons [11]. It may be possible that both dysmenor-
rhoea (painful menstruation) and endometriosis are
manifestations of outflow obstruction [9].
Role of increased inflammatory activity in the 
development of endometriosis
Peritoneal fluid (PF) in women with endometriosis is
marked by increased inflammation, including increased
volume of PF, increased concentration of white blood
cells and macrophages, and increased activation status of
these macrophages (reviewed by D'Hooghe and Hill
[12]). These activated peripheral mononuclear cells as
well as endometriotic cells in situ are hypothesised to
secrete various cytokines with pleiotropic biological activ-
ities. Cytokines are low molecular weight proteins or glyc-
oproteins typically synthesised by peritoneal
macrophages, lymphocytes, ectopic endometrial implants
or mesothelial cells of the peritoneum [13,14]. Usually,
inflammatory cytokines and growth factors are secreted
and culminate in recruitment of numerous cell types to
the peritoneal cavity [15]. Aberrant expression of several
cytokines by activated macrophages, such as interleukin
(IL)-1, IL-6, IL-8 and TNF-α in peritoneal fluid of women
with endometriosis compared to controls [16] may con-
tribute to a peritoneal microenvironment, which favours
the implantation of endometrial cells and the establish-
ment of endometriosis [17]. Indeed, as reviewed in the
next section, cytokines like IL-8 and TNF-alpha are known
to promote endometrial cell proliferation, endometrial
adhesion and angiogenesis. Not only peritoneal macro-
phages, but also endometriotic lesions and mesothelial
cells of peritoneal origin may secrete cytokines such as
Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1
(IL-1) in women with endometriosis. These cytokines in
turn modulate the stimulation of other cytokines and
chemokines such as Interleukin-8 (IL-8) and RANTES
(Regulated upon activation, normal T-cell expressed and
secreted). RANTES is a potent attractant and activator of
macrophages, T-lymphocytes and eosinophils [18,19],
while IL-8 promotes angiogenesis [20]. In one study [21],
a positive correlation was found between the rAFS stages
of endometriosis and the concentration of TNF-α in PF.
The concentration of TNF-α in PF was significantly higher
in patients with stage III/IV disease (168 pg/ml) than in
women with stage 1/II disease (60.2 pg/ml) or control
patients (3.3 pg/ml) [21]. TNF-α and IL-8 concentrations
in peritoneal fluid have also been reported to correlate
with the size and number of active lesions [22]. The
increased concentration of TNF-α reflects enhanced secre-
tory activity of the peritoneal macrophages and not just
the mere increase in the number of peritoneal macro-
phages [20].
Are changes in immunological/inflammatory 
mediators a cause or consequence of 
endometriosis?
Does endometriosis lead to inflammation caused by an
inappropriate and exaggerated immune response to
ectopic endometrial debris? Or is endometriosis caused
by peritoneal inflammation? Obviously, these cause-
effect relationships cannot be studied in women for ethi-
cal reasons. In baboons, current evidence suggests that
peritoneal inflammation is a consequence, not a cause of
endometriosis.
Firstly, in baboons, both spontaneous retrograde men-
struation and experimental intrapelvic injection of
endometrium are associated with intrapelvicPage 2 of 9
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concentration of white blood cells and inflammatory
cytokines) [23,24]. This peritoneal inflammatory effect is
observed within one month after intrapelvic injection of
endometrium (24), but disappears after 2 to 3 months
later [25]. Secondly, it has been reported that the WBC
concentration and proportion of macrophages and cyto-
toxic T cells is increased in the PF of baboons with spon-
taneous endometriosis [25,26]. Thirdly, the percentage of
CD4+ and IL2R+ cells has been shown to be increased in
the peripheral blood of baboons with stage II to IV
endometriosis, (both spontaneous long term endometri-
osis and induced) when compared to those with recent
spontaneous endometriosis (Stage I) or a normal pelvis.
Even if peritoneal inflammation is a consequence rather
than a cause of endometriosis [Fig. 1], the coexistence of
endometriosis and peritoneal inflammation may offer
new anti-inflammatory therapeutic options in the treat-
ment of endometriosis. In an earlier study in baboons, a
high dose of immunosuppression with azathioprin and
methylprednisolone during 3 months did not affect the
incidence of spontaneous endometriosis, the extent of
induced endometriosis, and had a marginal stimulatory
effect on the progression of spontaneous endometriosis
[27], suggesting that overall immunosuppression does
not have much effect on the incidence, prevalence or
degree of endometriosis. Similarly, there is no evidence
that the prevalence of endometriosis is higher in women
using long term immunosuppression. However, more
specific anti-inflammatory agents may affect the develop-
ment of endometriosis. For instance drugs suppressing
macrophage activation, such as verapamil (calcium chan-
nel blocking agent) and pentoxifylline, have been tested
in hamster and mice respectively [28,29]. Other drugs
have also been tested in rodents and nonhuman primates,
as is reported in the last section of this paper.
Role of the immune system in endometrial-
peritoneal adhesion
Quality of viable endometrial cells
It has been hypothesised that the quality of endometrial
cells in PF of women with endometriosis is different from
women with normal pelvis. Viable endometrial cells from
human endometriotic biopsies but not from human
endometrial biopsies are invasive in an in vitro collagen
invasion assay, probably because they have a higher pro-
portion of potentially invasive E-cadherin-negative epi-
thelial cells [30]. Inflammatory cytokines (TNF-alpha, IL-
8 and IL-6) produced by endometrial cells probably con-
tribute to this adhesion process [31-33]. IL-8 has been
shown to stimulate the adhesion of endometrial cells to
fibronectin [31]. TNF-α has been reported to also pro-
mote endometrial stromal cell proliferation in vitro [32]
and endometrial stromal cell adhesion to extracellular
matrix components [33]. TNF-α may induce IL-8 gene and
IL-8 protein expression in a dose-dependent manner, and
the stimulating effect of TNF-α on endometrial stromal
cell proliferation can be reversed by adding anti-IL8 anti-
bodies [30].
Does endometriosis then only occur among women with
a high degree of endometrial-peritoneal adhesion? This is
unknown at present, since it is impossible to study this
process in women in vivo. Debrock and colleagues [34]
reported a 80–100% success rate of endometrial-perito-
neal adhesion in cultured explants after 48 hours, regard-
less of the presence or absence of endometriosis. Witz et al
[35] showed endometrial adhesion occurs within 1 hour
and transmesothelial invasion occurs within 18 hours.
However, all these assays are merely descriptive and there
is a need to develop a quantitative in vitro assay to measure
endometrial-peritoneal adhesion.
Endometrial quality can also be affected by local estrogen
production in eutopic/ectopic endometrium. Indeed, the
expression of uncontrolled aromatase mRNA in endome-
triotic lesions [36] suggests that a local estrogenic milieu
is important in the development of endometriosis. It is
possible that persistent expression of aromatase and 17β-
hydroxysteroid dehydrogenase in endometriotic lesions
may also be driven by a T-like autoantibody response
[Table. 1]. Indeed, autoantibodies recognising T-like anti-
gens have been reported to be upregulated in endometri-
osis and may trigger the synthesis of cytokines such as IL-
1, TNF-α and IL-6, which in turn may induce the expres-
sion of aromatase and 17β-hydroxysteroid dehydrogenase
in endometriotic lesions [37].
Increased Angiogenesis
Macrophage derived cytokines like TGF-beta and VEGF
are suggested to contribute to the development of
endometriosis by promoting neovascularisation of
endometrial cells attached to the peritoneum [16,38].
Increased angiogenesis is reported to be common around
the peritoneal explants and increased angiogenic activity
has been observed in PF from women with endometriosis
[39]. For instance, vascular endothelial growth factor
(VEGF) has been detected in high concentration in PF
from women with moderate to severe endometriosis [40-
42], and is also secreted in endometriotic lesions, possibly
as a downstream consequence of proinflammatory
cytokine IL-1β activity [40,41]. VEGF is involved in the
development of blood vessels, that are critical in the
growth, and maintenance of ectopic endometrial
implants.Page 3 of 9
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A simplified view of the role of immune system in the development and maintenance of endometriosis. It illustrates the 
sequence of events leading to survival of endometrial cells in peritoneum, adherence, implantation, invasion and progression to 
disease.
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potential involvement of auto-antibodies
After attachment, endometrial cells invade the extracellu-
lar matrix, a process influenced by matrix metalloprotein-
ases (MMPs). MMPs are a group of enzymes important for
the control of extracellular matrix turnover [43]. MMPs
are upregulated by TNF-α and IL-1, which could contrib-
ute to the invasiveness of endometrial fragments in
women with endometriosis [44]. TNF-α may also contrib-
ute to the decreased expression of endogenous tissue
inhibitors of MMPs (TIMPS) under in vitro conditions
[45]. Both the downregulation of TIMP and increased
expression of MMPs may support the invasive growth of
endometriotic explants (Fig. 1). It has been postulated
that the hemopexin domain expressed by most MMPs is
involved in this process of MMP upregulation. Hemo-
pexin is a Thomsen-Friendenriech antigen bearing serum
protein that binds to jacalin. A hemopexin domain with
high sequence homology to plasma hemopexin is
expressed by MMPs except MMP-7 and can be recognised
by T-like autoantibodies in women with endometriosis
[37]. It has been postulated that the binding of T-like
autoantibodies to the hemopexin domain may lead to
dysregulation of the expression of MMPs and TIMPs in
ectopic lesions, leading to increased invasiveness of these
lesions in women with endometriosis (37). However, the
role of autoantibodies in the development of endometri-
osis remains an area of great interest and ignorance, as
reviewed before [46], even though new reports have sug-
gested that in women with endometriosis B-cell activity is
altered accompanied by increased incidence of autoanti-
bodies [47,48].
Altered immune function in women with 
endometriosis
Defective natural killer cells activity?
Retrograde menstruation occurs to some degree in all
women. Therefore, it has been hypothesised that the clear-
ance of endometrial cells within the pelvic cavity could be
decreased among women with endometriosis. A defective
cellular immunity (Fig. 1), especially impaired natural
killer (NK) cell function may contribute to the survival
and ectopic implantation of sloughed endometrial cells.
Wilson and colleagues [49] reported decreased NK cells
cytotoxicity in women with endometriosis. D'Hooghe
and colleagues [50] documented no difference in lym-
phocyte-mediated cytotoxicity and NK cell activity
between baboons with and without endometriosis. A dys-
function of two subclasses of NK cells may nurture
autoimmunity associated with endometriosis [51]. One
subset, NK T cells, is characterised by the capacity to kill
cell target and secrete cytokines, such as IL4 and IL-10,
which are important in the regulation of autoimmunity
[52]. Another subset of NK cells, CD16/CD56 NK cells
kills autologous dentritic cells (DCs) presenting self-anti-
gens to autoreactive T cells. The inability of NK cells in
eliminating autologous DCs expressing endometrial self-
antigens, may allow their presentation to autoreactive T
cells and the production of autoantibodies [51]. The fail-
ure of NK cells to scavenge autologous endometrial cells
may allow development of endometriosis. It has been
hypothesized that natural killer cells in the endometrium
can attack the implantation site of the embryo as it tries to
attach to the uterine wall and that autoantibodies can play
a role in this process [53]. However, a recent review has
shown that there is no proven relationship between abor-
tion, recurrent abortion and endometriosis [54], and at
present there is no proof that endometriosis-associated
subfertility is caused by impaired embryo implantation.
Decreased T Lymphocyte Cytotoxicity
CD4 T cells are divided into type1 (Th1) helper T cells
which secrete interleukin (IL)-2, IL-12 and interferon γ
and type2 (Th2) helper T cells, which secrete IL-4, 5, 6 10,
13 [38]. Cell-mediated immunity, including T-cell-medi-
ated cytotoxicity is activated or suppressed by cytokines
produced by Th1 and Th2 cells, respectively. Under nor-
mal conditions, there is a tightly regulatory control mech-
anism between Th1 and Th2 cells. For instance, Th1 cells
secrete IL-12, which activates cytotoxic NK cell activity,
whereas Th2 cells may reduce NK cell activity by produc-
ing IL-10 [38]. In women with endometriosis, Th2 helper
Table 1: Aberrantly regulated immune/inflammatory factors associated with the development of endometriosis
Factors Reference
Increased TNF-α, IL-8, IL-6, IL-1, TGF-β [31,32]
Increased RANTES, VEGF [19,40,41]
Increased Aromatase,17β-hydroxysteroid dehydrogenase [37]
Increased B cell function [47]
Increased T-like autoantibodies against hemopexin [37].
Increased MMPs [44]
Decreased TIMPs [45]
Increased IL-4, IL-10, sICAM-1 [38,51,57,58]Page 5 of 9
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mediated immunity by upregulating IL-4 and 10 secre-
tions in PF from women with endometriosis [38,55]. As a
result, decreased T cell cytotoxicity may allow implanta-
tion of endometrial cells in peritoneum.
Impaired immune-surveillance and abnormal apoptosis
The failure of immune cells to transmit death signals to
endometrial cells, and/or the ability of endometrial frag-
ments to avoid cell death may be associated with the
development of endometriosis. Indeed, in women with
endometriosis, it has been hypothesed that endometrial
cells in the peritoneal fluid avoid immunosurveillance
and implant into peritoneum [56]. It has been speculated
that lymphocytes can adhere to endometrial cells through
the Lymphocyte Function-Associated Antigen-1(LFA-1) –
Intercellular adhesion molecule-1 (ICAM-1) dependent
pathway and present them as a target to NK cells. Soluble
forms of ICAM-1 (s-ICAM-1) secreted by PF endometrial
cells/endometriotic lesions can also bind to LFA-1 pre-
senting lymphocytes and could prevent the recognition of
endometrial cells by these lymphocytes and prevent sub-
sequent NK cell-mediated cytotoxicity [57,58]. Further-
more, IL-6 secreted by endometriotic cells in concert with
interferon-γ may upregulate sICAM-1 production by mac-
rophages of patients with endometriosis [59]. As a result,
increased secretion of sICAM-1 may allow endometrial
fragments to evade immunosurveilance, survive and
implant.
Another major pathway in programmed cell death, Fas-
Fas Ligand (FasL) system, could also be abnormal in
women with endometriosis [60,61]. It has been specu-
lated that the expression of FasL by viable endometrial
cells induces apoptosis of T cells through ligation of Fas,
allowing endometrial fragments to escape cell death,
implant and develop to endometriotic lesions [62]. Inter-
estingly, Garcia-Velasco et al [62] showed that macro-
phage-conditioned media might stimulate Fas-Fas ligand
(FasL) expression by endometrial cells.
Relevance in clinical research
Biomarkers to predict endometriosis non-surgically
Presently, the diagnosis of endometriosis can be made
only by laparoscopy and biopsy of suspicious lesions with
subsequent histological confirmation of endometrial tis-
sue and there is no non-invasive way to diagnose this con-
dition. Laparascopy is minimally invasive procedure, but
requires general anaesthesia and surgical skills with
potential complications and procedural costs. Hence, a
non-surgical diagnostic tool would be of paramount ben-
efit to both physicians and patients.
Efforts to evaluate the diagnostic value of endometrial
markers for endometriosis have been hampered by the
lack of easy, reliable and quantitative techniques to assess
the expression levels of these markers in sample material.
Emerging proteomic techniques offer new approaches to
identifying biomarkers for the early detection and follow-
up of endometriosis.
Aromatase P450 mRNA has been identified as a candidate
diagnostic marker but low sensitivity and specificity
impair its application in clinical practice (Reviewed by
Brosens et al [63]). In a recent study [64], the measure-
ment of serum IL-6 levels and PF TNF-α levels could dis-
criminate between patients with endometriosis and those
without the disease. Endometriosis could be diagnosed if
TNF-alpha levels in PF were higher than 15 pg/ml (100%
sensitivity and 89% specificity) and if IL-6 levels in serum
were above 2 pg/ml (90% sensitivity and 67% specificity)
[64]. Potentially, the quantitation of autoantibodies
against endometrial cells could also provide a novel
method for the non-invasive diagnosis for endometriosis
[65]. However, more studies are needed to confirm that
this approach may be clinically useful. The role of Trans-
vaginal Ultrasonography (TVU) and Magnetic resonance
Imaging (MRI) in diagnosis and follow up of small
endometriotic lesions is limited at present, but represents
an interesting area of research [63].
New treatment options and future management of endometriosis
Endometriosis causes pelvic pain and infertility and can
be treated by surgery and by hormonal suppression (pro-
gestins, continuous use of oral contraceptives, danazol,
GnRH agonists), as reviewed recently [66]. A drug like
danazol also works as an immunosuppressive agent
(reviewed by D'Hooghe and Hill [66]). Indeed, the immu-
nologic effects of danazol have been studied in women
with endometriosis and adenomyosis and include a
decrease in serum immunoglobulins [67,68], a decrease
in serum C3, a rise in serum C4 levels [68], decreased
serum levels of autoantibodies against various phosphol-
ipid antigens [67,68], and decreased serum levels of
CA125 during treatment [69-72]. Danazol inhibits
peripheral blood lymphocyte proliferation in cultures
activated by T-cell mitogens but does not affect macro-
phage-dependent T-lymphocyte activation of B lym-
phocytes [73]. Danazol inhibits interleukin-1 (IL1) and
TNF production by monocytes in a dose-dependent man-
ner [74] and suppresses macrophage/monocyte-mediated
cytotoxicity of susceptible target cells in women with mild
endometriosis [75]. These immunological findings may
be important in the remission of endometriosis with dan-
azol treatment and may offer an explanation of the effect
of danazol in the treatment of a number of autoimmune
diseases, including hereditary angioedema [76], autoim-
mune hemolytic anemia [77], systemic lupus erythemato-
sus, and idiopathic thrombocytopenic purpura [78,79].Page 6 of 9
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cost, side effects and recurrence of endometriosis after the
cessation of treatment. Therefore, there is need for new
drugs that treat endometriosis-associated pain and infer-
tility without inhibition of ovulation. Future potential tar-
gets in the treatment or management of endometriosis
may be inflammatory cytokines, MMPs, adhesion and
growth factors [80,38]. Pentoxifylline has been shown to
reduce endometriotic implant growth without inducing
hypoestrogenism in both humans and hamsters [38]. In a
recent study, Hornung and colleagues [81] demonstrated
that Thiazolidinedione (TZD) significantly reduced leu-
kocyte infiltration in the mouse model with endometrio-
sis. Inhibition of TNF-alpha activity has also been a new
target in the prevention and treatment of endometriosis.
Experimental endometriosis in rats was treated with
recombinant human tumour necrosis factor-binding pro-
tein-1 (r-hTBP-1), a soluble form of tumour necrosis fac-
tor-α receptor type-1 [82]. It was demonstrated that r-
hTBP-1 could reduce the size of endometriotic-like perito-
neal lesions by 64% [82]. Similarly, a study carried out in
baboons showed that r-hTBP-1 effectively inhibited the
development of endometriosis and endometriosis-related
adhesions [83]. The potential of etanercept, a soluble TNF
receptor (TNFR) fusion protein, for the treatment of
endometriosis is also being considered [84].
Conclusion
Understanding the involvement of the immune system in
the development of endometriosis may help to under-
stand the pathogenesis and spontaneous evolution of this
condition. At present, most evidence suggests that pelvic
inflammation and other immunological changes are a
consequence of endometriosis. The development of a
non-invasive diagnostic tools based on cytokines and
autoantibodies could be of great benefit in the clinical
management of endometriosis. Therapeutic strategies to
eliminate the inflammatory reaction associated with
endometriosis could lead to new treatment options for
endometriosis.
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